Raymond James & Associates Compugen LTD Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Compugen LTD stock. As of the latest transaction made, Raymond James & Associates holds 83,825 shares of CGEN stock, worth $140,826. This represents 0.0% of its overall portfolio holdings.
Number of Shares
83,825
Previous 84,625
0.95%
Holding current value
$140,826
Previous $142,000
6.34%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding CGEN
# of Institutions
80Shares Held
13.4MCall Options Held
44.9KPut Options Held
8.1K-
Silverarc Capital Management, LLC1.62MShares$2.73 Million0.6% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.28MShares$2.15 Million0.0% of portfolio
-
Taylor Frigon Capital Management LLC1.09MShares$1.84 Million0.85% of portfolio
-
Macquarie Group LTD Australia, C31.02MShares$1.71 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD990KShares$1.66 Million0.06% of portfolio
About COMPUGEN LTD
- Ticker CGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 86,624,600
- Market Cap $146M
- Description
- Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...